• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by IceCure Medical Ltd.

    3/31/26 4:15:08 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care
    Get the next $ICCM alert in real time by email
    Form D
    FORM D
    Notice of Exempt Offering of Securities

    UNITED STATES SECURITIES
    AND EXCHANGE COMMISSION
    Washington, D.C.

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated Average burden hours per response: 4.0
    1. Issuer's Identity
    CIK (Filer ID Number)Previous Name(s)Checkbox checkedNoneEntity Type
    0001584371
    Radio button checkedCorporation
    Radio button not checked Limited Partnership
    Radio button not checked Limited Liability Company
    Radio button not checked General Partnership
    Radio button not checked Business Trust
    Radio button not checkedOther 
    Name of Issuer
     IceCure Medical Ltd.
    Jurisdiction of Incorporation/Organization
    ISRAEL 
    Year of Incorporation/Organization
    Radio button checkedOver Five Years Ago
    Radio button not checkedWithin Last Five Years (Specify Year)
     
    Radio button not checkedYet to Be Formed
     
      
      
     
    2. Principal Place of Business and Contact Information
    Name of Issuer
     IceCure Medical Ltd.
    Street Address 1Street Address 2
     7 HA'ESHEL ST
     
    CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
     CAESAREA
     ISRAEL
     
     3079504
     +972.4.6230333 




    3. Related Persons

    Last NameFirst NameMiddle Name
    Shamir
    Eyal
    Street Address 1Street Address 2
     7 HA'ESHEL ST 
     PO BOX 3163
    CityState/Province/CountryZIP/Postal Code
     CAESAREA
     ISRAEL
     3079504
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Chief Executive Officer



    Last NameFirst NameMiddle Name
    Tsimerman
    Ronen
    Street Address 1Street Address 2
     7 HA'ESHEL ST 
     
    CityState/Province/CountryZIP/Postal Code
     CAESAREA
     ISRAEL
     3079504
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Chief Financial Officer



    Last NameFirst NameMiddle Name
    Mayron
    Ron
    Street Address 1Street Address 2
     7 HA'ESHEL ST 
     PO BOX 3163
    CityState/Province/CountryZIP/Postal Code
     CAESAREA
     ISRAEL
     3079504
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Chairman



    Last NameFirst NameMiddle Name
    Levav
    Shay
    Street Address 1Street Address 2
     7 HA'ESHEL ST 
     PO BOX 3163
    CityState/Province/CountryZIP/Postal Code
     CAESAREA
     ISRAEL
     3079504
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Chief Operating Officer



    Last NameFirst NameMiddle Name
    Muchnik
    Naum
    Street Address 1Street Address 2
     7 HA'ESHEL ST 
     PO BOX 3163
    CityState/Province/CountryZIP/Postal Code
     CAESAREA
     ISRAEL
     3079504
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Vice President, Research, Development and Engineering



    Last NameFirst NameMiddle Name
    Tel-Tzure
    Tlalit Bussi
    Street Address 1Street Address 2
     7 HA'ESHEL ST 
     PO BOX 3163
    CityState/Province/CountryZIP/Postal Code
     CAESAREA
     ISRAEL
     3079504
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Vice President, Business Development and Global Marketing



    Last NameFirst NameMiddle Name
    Dotan
    Merav Nir
    Street Address 1Street Address 2
     7 HA'ESHEL ST 
     PO BOX 3163
    CityState/Province/CountryZIP/Postal Code
     CAESAREA
     ISRAEL
     3079504
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Vice President, Human Resources



    Last NameFirst NameMiddle Name
    Good
    Shad
    Street Address 1Street Address 2
     7 HA'ESHEL ST 
     PO BOX 3163
    CityState/Province/CountryZIP/Postal Code
     CAESAREA
     ISRAEL
     3079504
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Vice President, Sales for North America



    Last NameFirst NameMiddle Name
    Chan
    Vincent Chun Hung
    Street Address 1Street Address 2
     7 HA'ESHEL ST 
     PO BOX 3163
    CityState/Province/CountryZIP/Postal Code
     CAESAREA
     ISRAEL
     3079504
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Huang
    Yang
    Street Address 1Street Address 2
     7 HA'ESHEL ST 
     PO BOX 3163
    CityState/Province/CountryZIP/Postal Code
     CAESAREA
     ISRAEL
     3079504
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Levita
    Sharon
    Street Address 1Street Address 2
     7 HA'ESHEL ST 
     PO BOX 3163
    CityState/Province/CountryZIP/Postal Code
     CAESAREA
     ISRAEL
     3079504
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Malca
    Yonatan
    Street Address 1Street Address 2
     7 HA'ESHEL ST 
     PO BOX 3163
    CityState/Province/CountryZIP/Postal Code
     CAESAREA
     ISRAEL
     3079504
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)





    4. Industry Group
     Radio button not checkedAgriculture
    Banking & Financial Services
     Radio button not checked Commercial Banking
     Radio button not checked Insurance
     Radio button not checkedInvesting
     Radio button not checked Investment Banking
     Radio button not checked Pooled Investment Fund

     Radio button not checkedOther Banking & Financial Services
    Radio button not checked Business Services
    Energy
     Radio button not checked Coal Mining
     Radio button not checked Electric Utilities
     Radio button not checked Energy Conservation
     Radio button not checked Environmental Services
     Radio button not checked Oil & Gas
     Radio button not checked Other Energy
    Health Care
     Radio button checked Biotechnology
     Radio button not checked Health Insurance
     Radio button not checked Hospitals & Physicians
     Radio button not checked Pharmaceuticals
     Radio button not checked Other Health Care
       
       
       
      
    Radio button not checked Manufacturing
    Real Estate
     Radio button not checkedCommercial
     Radio button not checkedConstruction
     Radio button not checkedREITS & Finance
     Radio button not checkedResidential
    Radio button not checkedOther Real Estate
    Radio button not checked Retailing
    Radio button not checkedRestaurants
    Technology
    Radio button not checked Computers
    Radio button not checked Telecommunications
    Radio button not checked Other Technology
    Travel
    Radio button not checked Airlines & Airports
    Radio button not checked Lodging & Conventions
    Radio button not checked Tourism & Travel Services
    Radio button not checked Other Travel
    Radio button not checkedOther

      
       
    5. Issuer Size
    Revenue RangeAggregate Net Asset Value Range
    Radio button not checkedNo RevenuesRadio button not checked No Aggregate Net Asset Value
    Radio button not checked $1 - $1,000,000Radio button not checked$1 - $5,000,000
    Radio button checked $1,000,001 - $5,000,000Radio button not checked $5,000,001 - $25,000,000
    Radio button not checked$5,000,001 - $25,000,000Radio button not checked $25,000,001 - $50,000,000
    Radio button not checked$25,000,001 - $100,000,000Radio button not checked $50,000,001 - $100,000,000
    Radio button not checked Over $100,000,000Radio button not checked Over $100,000,000
    Radio button not checked Decline to Disclose Radio button not checkedDecline to Disclose
    Radio button not checked Not ApplicableRadio button not checked Not Applicable

     
    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
    Checkbox not checkedRule 504(b)(1) (not (i), (ii)
    or (iii))
    Checkbox checkedRule 506(b)      
    Checkbox not checkedRule 504 (b)(1)(i) Checkbox not checkedRule 506(c)
    Checkbox not checkedRule 504 (b)(1)(ii) Checkbox not checkedSecurities Act Section 4(a)(5)
    Checkbox not checkedRule 504 (b)(1)(iii)Checkbox not checkedInvestment Company Act Section 3(c)
     
     

    7. Type of Filing
    Checkbox checked New Notice Date of First Sale 
    2026-03-26
    Checkbox not checked First Sale Yet to Occur
    Checkbox not checked Amendment


     
     
    8. Duration of Offering
    Does the Issuer intend this offering to last more than one year? Radio button not checked Yes Radio button checked No
     
     
    9. Type(s) of Securities Offered (select all that apply)
    Checkbox not checkedPooled Investment Fund InterestsCheckbox not checkedEquity
    Checkbox not checkedTenant-in-Common Securities Checkbox not checkedDebt
    Checkbox not checkedMineral Property SecuritiesCheckbox checkedOption, Warrant or Other Right to Acquire Another Security
    Checkbox checkedSecurity to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire SecurityCheckbox not checkedOther (describe)
     
     
     
    10. Business Combination Transaction
    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Radio button not checked Yes Radio button checked No
    Clarification of Response (if Necessary)
     
     
     
    11. Minimum Investment
    Minimum investment accepted from any outside investor$
     0
    USD

    12. Sales Compensation
    Recipient Recipient CRD NumberCheckbox not checkedNone
     A.G.P./Alliance Global Partners
     000008361
    (Associated) Broker or DealerCheckbox checkedNone(Associated) Broker or Dealer CRD Number Checkbox checkedNone
      
      
    Street Address 1      Street Address 2
    590 Madison Avenue
    28 Floor
    City State/Province/CountryZIP/Postal Code
     New York
     NEW YORK
     10020
    State(s) of SolicitationCheckbox not checkedAll StatesCheckbox checkedForeign/Non-US
     
    CALIFORNIA
    CONNECTICUT
    FLORIDA
    ILLINOIS
    NEW YORK




    13. Offering and Sales Amounts
     
    Total Offering Amount $
    4000000
    USDCheckbox not checkedIndefinite
    Total Amount Sold $
    4000000
    USD
    Total Remaining to be Sold $
    0
    USDCheckbox not checkedIndefinite
    Clarification of Response (if Necessary)
      
     
    14. Investors

    Checkbox not checkedSelect if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
    Number of such non-accredited investors who already have invested in the offering
       
      Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    5
     
    15. Sales Commissions & Finders’ Fees Expenses
    Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
    Sales Commissions$
    280000
    USDCheckbox not checkedEstimate
    Finders' Fees$
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     
     

    16. Use of Proceeds
    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
     $ 
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     

    Signature and Submission
     
    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
    Terms of Submission 
     In submitting this notice, each Issuer named above is: 
     
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).
     
    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.
    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.
     
    IssuerSignatureName of SignerTitleDate
    IceCure Medical Ltd./s/ Eyal ShamirEyal ShamirChief Executive Officer2026-03-31




    Get the next $ICCM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ICCM

    DatePrice TargetRatingAnalyst
    2/2/2022$5.65Buy
    Brookline Capital
    9/22/2021$14.50Buy
    Alliance Global Partners
    More analyst ratings

    $ICCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Brookline Capital initiated coverage on Icecure Medical with a new price target

    Brookline Capital initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $5.65

    2/2/22 11:13:08 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    Alliance Global Partners initiated coverage on Icecure Medical with a new price target

    Alliance Global Partners initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $14.50

    9/22/21 8:10:09 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

    CAESAREA, Israel, March 26, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into securities purchase agreements with healthcare focused institutional investors for the purchase and sale of 8,000,000 ordinary shares at a purchase price of $0.50 per share in a registered direct offering. The gross proceeds from the offering are expected to be approximately $4.0 million, before deducting placement agent fees and other offering expenses. In addition, in a concurrent private pla

    3/26/26 8:00:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates

    At a median follow-up of four years, 89.4% recurrence-free rate in patients with tumors ≤3 cm and no prior kidney cancer; 83.9% recurrence-free rate for general study populationFull analysis of results to be presented at European Conference of Interventional Oncology 2026 in Basel, SwitzerlandData supports broader commercial adoption of ProSense® as a minimally invasive treatment for small renal masses in markets where it is approved for kidney cancer, including the U.S. and Europe CAESAREA, Israel, March 25, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by

    3/25/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Appoints Meir Peleg as Chief Financial Officer

    Meir Peleg brings over 20 years of financial leadership and experience including with Nasdaq listed companiesIceCure intends to appoint Dr. Richard Fine as Medical Director CAESAREA, Israel, March 24, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the appointment of Mr. Meir Peleg as its Chief Financial Officer ("CFO"), effective May 17, 2026. The appointment comes as IceCure is

    3/24/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    SEC Filings

    View All

    SEC Form F-1 filed by IceCure Medical Ltd.

    F-1 - IceCure Medical Ltd. (0001584371) (Filer)

    4/1/26 4:30:39 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form D filed by IceCure Medical Ltd.

    D - IceCure Medical Ltd. (0001584371) (Filer)

    3/31/26 4:15:08 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by IceCure Medical Ltd.

    424B5 - IceCure Medical Ltd. (0001584371) (Filer)

    3/27/26 8:49:33 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Malca Yonatan

    3 - IceCure Medical Ltd. (0001584371) (Issuer)

    3/25/26 5:16:30 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Huang Yang

    3 - IceCure Medical Ltd. (0001584371) (Issuer)

    3/25/26 5:15:46 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Chan Vincent Chun Hung

    3 - IceCure Medical Ltd. (0001584371) (Issuer)

    3/25/26 5:15:14 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    Financials

    Live finance-specific insights

    View All

    IceCure Reports 2025 Full Year Financial & Operational Results

    Record 4th quarter and full year sales of $1.3 million and $3.4 million, respectivelyStrong commercial momentum for ProSense® in the U.S. and globally following FDA clearance in low-risk breast cancer and medical society recommendations 30 hybrid commercial-clinical sites to be added for FDA approved post-marketing study in addition to growing pipeline of potential commercial customersIceCure Applies to Expand Regulatory Approval in Canada for ProSense® Cryoablation to Include the Treatment of Low-Risk Breast Cancer  Conference call to be held today at 11:00 am Eastern TimeCAESAREA, Israel, March 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the

    3/17/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

    CAESAREA, Israel, March 10, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2025 before the Nasdaq Stock Market opens on Tuesday, March 17, 2026. The Company will also discuss such results and other corporate developments on a conference call at 11:00 a.m. EDT on the same day. Conference call & webcast info:Tuesday, March 17, 2026, at 11:00 am EDTUS: 1-888-407-2553Is

    3/10/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

    Momentum building in the U.S. and rising interest globally following landmark FDA marketing authorization for local cryoablation treatment of low-risk breast cancer Demand for ProSense® systems expected to accelerate in 2026 Total U.S. population of approximately 200,000 patients, includes women aged 70+, those not suitable for surgery and benign breast tumors  Conference call to be held today, November 19, 2025 at 10:00 am Eastern Time CAESAREA, Israel, Nov. 19, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal

    11/19/25 8:54:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    Leadership Updates

    Live Leadership Updates

    View All

    IceCure Appoints Meir Peleg as Chief Financial Officer

    Meir Peleg brings over 20 years of financial leadership and experience including with Nasdaq listed companiesIceCure intends to appoint Dr. Richard Fine as Medical Director CAESAREA, Israel, March 24, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the appointment of Mr. Meir Peleg as its Chief Financial Officer ("CFO"), effective May 17, 2026. The appointment comes as IceCure is

    3/24/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

    Ronen Tsimerman will continue as CFO until successor is appointed CAESAREA, Israel, Feb. 9, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that after nearly a decade of service with IceCure, Chief Financial Officer Ronen Tsimerman has informed the Company of his decision to leave the Company to pursue new opportunities. The Company has initiated a search for a new Chief Financial Officer and has identified compelling candidates with significant experience commercializing disruptive technolo

    2/9/26 4:30:00 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America

    Mr. Shad Good brings nearly 20 years of medical device sales and leadership experience, including as U.S. Senior Director of Sales at a global leader in minimally invasive breast diagnostic and therapeutic systemsImmediate responsibility is to build out the sales infrastructure as the Company awaits the FDA response to its regulatory filing for early-stage low risk breast cancer in patients who are at high risk for surgery as well as the FDA's response to the final ICE3 results which are due in 2024 CAESAREA, Israel, Aug. 28, 2023 /PRNewswire/ -- IceCure Medical Ltd. ("IceCure" or the "Company") (NASDAQ:ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology tha

    8/28/23 8:00:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by IceCure Medical Ltd.

    SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

    11/14/24 9:38:43 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by IceCure Medical Ltd. (Amendment)

    SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

    2/14/23 8:46:31 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by IceCure Medical Ltd. (Amendment)

    SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

    1/24/23 5:04:22 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care